Stock Ratings / Health Care / SCNX / forecast

SKYE (36) ALZN (47) LGVN (32) ACXP (39) ⌘ Pro Terminal →

Scienture Holdings Inc. (SCNX) 12-Month Stock Forecast & Price Target Cone

Q: Is SCNX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Scienture Holdings Inc. (NASDAQ: SCNX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $3.49 (+2.65% 1D, market cap $5.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SCNX ranks #597 in composite RQD confidence.

Q: How does SCNX compare to SKYE and ALZN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SCNX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of 76.8%, and ROIC of -35.0%. By comparison, SKYE (Skye Bioscience Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M) and ALZN (Alzamend Neuro Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $5.9M). Among the 5-stock peer group, SCNX leads on earnings multiple (N/A) while SCNX leads on capital efficiency (-35.0% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for SCNX?

Per SCNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001382574), Scienture Holdings Inc. generated $431.6K in revenue (+215.9% YoY), -$41.5M in net income, and -$13.4M in free cash flow against $84.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is SCNX trading relative to its 50-day, 200-day, and 52-week technical levels?

SCNX last traded at $3.49 (+2.65% on volume of 59,144 shares), positioning the stock -44.87% below its 50-day simple moving average ($6.33) and -62.02% below its 200-day simple moving average ($9.19). Across its 52-week range of $2.64 to $27.75, SCNX sits at the 3.4% percentile with a 14-day RSI of 32.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.05 to $3.93).

Q: What is SCNX's 12-month stock price target?

Scienture Holdings Inc. (SCNX) carries a 12-month consensus base price target of $3.24 (-7.2% from $3.49), with a bull-case target of $29.14 and a bear-case floor of $2.53.

Q: Is SCNX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates SCNX D- (Sell — SELL) with an RQD Confidence score of 42/100.

$3.49 +2.65% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.50

Scienture Holdings Inc. (SCNX) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $5.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.50 (+0.29%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SCNX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY SCNX SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (31% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 32 (OVERSOLD (<32))

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$3.76-10.6% Next Q

Q2 (-2Q)

Grade D$3.36-14.3% Next Q

Q3 (-1Q)

Grade D$2.88+21.2% Next Q

Current

Grade D-$3.49-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SCNX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SCNX currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.33) and Max Pain ($3.66) forces dealer call-delta covering toward $29.14.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SCNX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SCNX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your SCNX Position Size: $10,000

Shares at $3.49: 2865.3 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $2.53

$7,249

$-2,751 (-27.5%)

12M Consensus BaseTarget $3.24

$9,284

$-716 (-7.2%)

12M Bull Case BreakoutTarget $29.14

$83,496

+$73,496 (+735.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$3	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$27	69%	B
JP MorganUS Large-Cap Research	SELL	$3	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SCNX)

✓Walkthrough of SCNX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SCNX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -64.28%📐 HORIZONTAL RANGE

2026-10-30O $3.42H $3.49L $3.17C $3.49VOL 11.4K

RES: $12.21SUP: $2.37SMA50: $6.33SMA200: $9.19

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SCNX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SCNX Butterfly Map → + Track SCNX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SCNX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SCNX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SCNX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SCNX)

Health Care Rank #597 of 1016 ⚔️ SKYE vs SCNX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SCNX vs. SKYE, ALZN, LGVN, ACXP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Scienture Holdings Inc. (SCNX) ranks #597 by composite RQD confidence (42/100, grade D-) and #933 by equity capitalization ($5.7M). Within this direct 5-issuer industry benchmark cohort, SCNX leads on earnings valuation at N/A trailing P/E, while SCNX leads on capital efficiency and profitability with -35.0% ROIC and 76.8% gross margin. ALZN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with SCNX at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SCNX ACTIVE Scienture Holdings Inc.	D-	42/100	—	76.8%	-35.0%	+2.65%	$5.7M	Benchmark Subject
SKYE Skye Bioscience Inc.	D-	36/100	—	—	-35.0%	-13.82%	$5.8M	/skye-vs-scnx →
ALZN Alzamend Neuro Inc.	D	47/100	—	—	-35.0%	+2.52%	$5.9M	/alzn-vs-scnx →
LGVN Longeveron Inc. (Class A)	E	32/100	—	67.0%	-35.0%	-1.68%	$5.6M	/lgvn-vs-scnx →
ACXP Acurx Pharmaceuticals Inc.	D-	39/100	—	—	-35.0%	0.00%	$5.9M	/acxp-vs-scnx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001382574

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scienture Holdings Inc. (SCNX) reported GAAP revenue of $431.6K (+215.9% vs. FY2024 revenue of $136.6K , and -68.4% cumulative change since FY2023) , GAAP net income of -$41.5M, operating cash flow of -$13.4M, and free cash flow of -$13.4M (+6.3% YoY). On the balance sheet, SCNX closed FY2025 with $84.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$431.6K	-$41.5M	-$13.4M	-$13.4M	$84.2M	—
FY2024 (FY)	2024-12-31	$136.6K	$13.6M	-$14.3M	-$14.3M	$104.9M	—
FY2023 (FY)	2023-12-31	$1.4M	-$17.8M	-$2.2M	-$2.2M	—	—

3. SCNX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SCNX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Scienture Holdings Inc. (NASDAQ: SCNX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $3.49 (+2.65% 1D, market cap $5.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SCNX ranks #597 in composite RQD confidence.

How does SCNX compare to SKYE and ALZN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SCNX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of 76.8%, and ROIC of -35.0%. By comparison, SKYE (Skye Bioscience Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M) and ALZN (Alzamend Neuro Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $5.9M). Among the 5-stock peer group, SCNX leads on earnings multiple (N/A) while SCNX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SCNX?

Per SCNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001382574), Scienture Holdings Inc. generated $431.6K in revenue (+215.9% YoY), -$41.5M in net income, and -$13.4M in free cash flow against $84.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SCNX trading relative to its 50-day, 200-day, and 52-week technical levels?

SCNX last traded at $3.49 (+2.65% on volume of 59,144 shares), positioning the stock -44.87% below its 50-day simple moving average ($6.33) and -62.02% below its 200-day simple moving average ($9.19). Across its 52-week range of $2.64 to $27.75, SCNX sits at the 3.4% percentile with a 14-day RSI of 32.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.05 to $3.93).

SCNX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is SCNX's 12-month stock price target?

Scienture Holdings Inc. (SCNX) carries a 12-month consensus base price target of $3.24 (-7.2% from $3.49), with a bull-case target of $29.14 and a bear-case floor of $2.53.

Is SCNX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates SCNX D- (Sell — SELL) with an RQD Confidence score of 42/100.

Direct Sub-Reports: SCNX RQD Cockpit SCNX 12M Forecast SCNX Earnings & Move SCNX Dividends & DRIP SCNX Insiders & 13F SCNX Whale Options SCNX Profit Sankey SCNX News & Why